AIMS: This study was conducted to determine whether galectin-3, a β-galactoside-binding lectin, plays a role in the pathogenesis of heart failure (HF). METHODS AND RESULTS: Galectin-3 was measured at baseline (n = 1650), after 4 months (n = 1346), and after 12 months (n = 1097) in the Valsartan Heart Failure Trial (Val-HeFT). Galectin-3 levels at baseline ranged from 4.8 to 53 ng/mL. Higher levels were associated with features of worse HF. In a fully adjusted Cox regression model comprising 23 other prognostic variables, baseline galectin-3 was not associated with the risks of all-cause mortality, the composite of the first morbid event, or hospitalization for HF. However, when changes in galectin-3 over time were examined, the increases in galectin-3 between baseline and 4 months were independently and significantly associated with the risks of subsequent all-cause mortality, first morbid event, and hospitalizations for HF, even after adjusting for all baseline and concurrent changes in all variables including estimated glomerular filtration rate (eGFR) and NT-proBNP. The strongest correlate of galectin-3 levels was eGFR, which accounted for 20% of the variability in galectin-3 levels at baseline. There was a significant interaction (P = 0.03) between baseline galectin-3 and the effect of valsartan on hospitalizations for HF. Valsartan caused a significant 44% reduction in hospitalizations for HF in patients with galectin-3 levels below the median level of 16.2 ng/mL, but not in patients with levels above the median. CONCLUSIONS:Galectin-3 levels are elevated in a substantial proportion of patients with HF, particularly those with more severe HF and renal dysfunction. Galectin-3 increased over time in this cohort, and the increase was independently associated with worse outcomes. Valsartan use was associated with a reduction in hospitalizations for HF in patients with low galectin-3, but not in those with higher levels of galectin-3.
RCT Entities:
AIMS: This study was conducted to determine whether galectin-3, a β-galactoside-binding lectin, plays a role in the pathogenesis of heart failure (HF). METHODS AND RESULTS:Galectin-3 was measured at baseline (n = 1650), after 4 months (n = 1346), and after 12 months (n = 1097) in the ValsartanHeart Failure Trial (Val-HeFT). Galectin-3 levels at baseline ranged from 4.8 to 53 ng/mL. Higher levels were associated with features of worse HF. In a fully adjusted Cox regression model comprising 23 other prognostic variables, baseline galectin-3 was not associated with the risks of all-cause mortality, the composite of the first morbid event, or hospitalization for HF. However, when changes in galectin-3 over time were examined, the increases in galectin-3 between baseline and 4 months were independently and significantly associated with the risks of subsequent all-cause mortality, first morbid event, and hospitalizations for HF, even after adjusting for all baseline and concurrent changes in all variables including estimated glomerular filtration rate (eGFR) and NT-proBNP. The strongest correlate of galectin-3 levels was eGFR, which accounted for 20% of the variability in galectin-3 levels at baseline. There was a significant interaction (P = 0.03) between baseline galectin-3 and the effect of valsartan on hospitalizations for HF. Valsartan caused a significant 44% reduction in hospitalizations for HF in patients with galectin-3 levels below the median level of 16.2 ng/mL, but not in patients with levels above the median. CONCLUSIONS:Galectin-3 levels are elevated in a substantial proportion of patients with HF, particularly those with more severe HF and renal dysfunction. Galectin-3 increased over time in this cohort, and the increase was independently associated with worse outcomes. Valsartan use was associated with a reduction in hospitalizations for HF in patients with low galectin-3, but not in those with higher levels of galectin-3.
Authors: Anahita Ghorbani; Vijeta Bhambhani; Robert H Christenson; Wouter C Meijers; Rudolf A de Boer; Daniel Levy; Martin G Larson; Jennifer E Ho Journal: J Am Coll Cardiol Date: 2018-12-25 Impact factor: 24.094
Authors: Omar F AbouEzzeddine; Phillip Haines; Susanna Stevens; Jose Nativi-Nicolau; G Michael Felker; Barry A Borlaug; Horng H Chen; Russell P Tracy; Eugene Braunwald; Margaret M Redfield Journal: JACC Heart Fail Date: 2015-03 Impact factor: 12.035
Authors: A Rogier van der Velde; Wouter C Meijers; Jennifer E Ho; Frank P Brouwers; Michiel Rienstra; Stephan J L Bakker; Anneke C Muller Kobold; Dirk J van Veldhuisen; Wiek H van Gilst; Pim van der Harst; Rudolf A de Boer Journal: Heart Date: 2016-04-15 Impact factor: 5.994
Authors: Casey M Rebholz; Elizabeth Selvin; Menglu Liang; Christie M Ballantyne; Ron C Hoogeveen; David Aguilar; John W McEvoy; Morgan E Grams; Josef Coresh Journal: Kidney Int Date: 2017-08-31 Impact factor: 10.612
Authors: Jonathan Beaudoin; Jagmeet P Singh; Jackie Szymonifka; Qing Zhou; Robert A Levine; James L Januzzi; Quynh A Truong Journal: Can J Cardiol Date: 2016-06-02 Impact factor: 5.223
Authors: Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky Journal: J Am Coll Cardiol Date: 2020-06-02 Impact factor: 24.094